Capital International Sarl Buys Shares of 73,393 Bristol-Myers Squibb (NYSE:BMY)

Capital International Sarl purchased a new stake in shares of Bristol-Myers Squibb (NYSE:BMYGet Rating) in the 1st quarter, Holdings Channel reports. The fund purchased 73,393 shares of the biopharmaceutical company’s stock, valued at approximately $5,360,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Capital International Ltd. CA purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $3,926,000. Capital Group International Inc. CA purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $53,895,000. Capital International Investors purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $1,672,455,000. Orion Portfolio Solutions LLC increased its position in shares of Bristol-Myers Squibb by 10.9% during the 1st quarter. Orion Portfolio Solutions LLC now owns 15,046 shares of the biopharmaceutical company’s stock valued at $1,099,000 after purchasing an additional 1,484 shares during the last quarter. Finally, Sawgrass Asset Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the 1st quarter valued at about $1,296,000. Hedge funds and other institutional investors own 76.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BMY. Citigroup reissued a “buy” rating and issued a $90.00 target price on shares of Bristol-Myers Squibb in a report on Friday, June 3rd. Bank of America increased their target price on shares of Bristol-Myers Squibb from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, June 6th. Atlantic Securities increased their target price on shares of Bristol-Myers Squibb from $83.00 to $87.00 and gave the stock an “overweight” rating in a report on Monday. BMO Capital Markets increased their target price on shares of Bristol-Myers Squibb from $92.00 to $94.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Berenberg Bank lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and cut their price objective for the company from $82.00 to $76.00 in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Moderate Buy” and a consensus price target of $76.36.

Bristol-Myers Squibb Stock Down 0.8 %

NYSE BMY opened at $70.47 on Thursday. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.34 and a current ratio of 1.44. The company has a market capitalization of $150.47 billion, a P/E ratio of 23.41, a P/E/G ratio of 1.49 and a beta of 0.43. Bristol-Myers Squibb has a one year low of $53.22 and a one year high of $80.59. The stock has a 50 day moving average price of $72.76 and a 200-day moving average price of $73.96.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last posted its earnings results on Wednesday, July 27th. The biopharmaceutical company reported $1.93 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.14. The firm had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.50 billion. Bristol-Myers Squibb had a return on equity of 49.31% and a net margin of 14.04%. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.93 EPS. As a group, equities analysts predict that Bristol-Myers Squibb will post 7.51 EPS for the current fiscal year.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Further Reading

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.